LMG Life Scienceshonored Mayer Brown at its 12th annual awards ceremony, which recognizes the groundbreaking work of leading law firms in the life sciences sector over the past year. The firm received an "Impact Case" award for its successful representation of Galderma against MedyTox in a post-grant review (PGR) proceeding before the US Patent Trial and Appeal Board (PTAB) involving a patent owned by MedyTox covering animal-protein-free botulinum toxin compositions.
During the PGR, MedyTox cancelled the originally granted claims but sought to amend them. After adopting Galderma's proposed construction of a key claim term, the PTAB found the proposed amended claims to be unpatentable because, among other things, their full scope was not enabled. The US Court of Appeals for the Federal Circuit affirmed in a precedential decision. The Federal Circuit's decision was the first to apply the Supreme Court's new enablement test articulated inAmgen v. Sanofi.
The team was led by partner Joe Mahoney (Charlotte) and included partners Erick Palmer and Amanda Streff Bonner (both Chicago), associate Cecilia Rambarat (Charlotte), and David Banchik and Jessica Mikus (both Galderma).